Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has established a Nomination Committee under its board of directors to enhance its corporate governance structure. This committee is tasked with selecting and recommending candidates for the company’s directors and senior management, thereby ensuring a robust leadership framework that aligns with the company’s strategic goals.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating within the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products and medical devices, with a strong emphasis on innovation and corporate governance.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more data about 2196 stock on TipRanks’ Stock Analysis page.